MENU

Sirtex Medical soars

Sirtex Medical (ASX: SRX) was one of the best performing stocks in the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) during the last financial year with its share price soaring from just over $6 to nearly $12, providing shareholders with a return of 97% for the 12 months.

Sirtex’s growing share price was in response to strong increases in sales of its SIR-Spheres, which are an innovative form of radiation therapy for treating liver cancer. Growing sales volumes look set to continue with today’s announcement that dose sales grew 13.1% in the fourth quarter. Sirtex has now had 36 consecutive quarters of dose sales growth!

Investing in the biotech sector is not for the fainthearted however, with last financial year seeing some previously high flying biotech shares fall significantly. Respiratory disease drug maker Pharmaxis’s  (ASX: PXS) share price plunged around 85% in response to regulatory issues, while promising diversified biotech Starpharma Holdings (ASX: SPL) lost over 30% as some investors became concerned by results from a Phase 2 trial.

Foolish takeaway

Investing in the biotech sector is rarely smooth sailing and many great ideas never make it to market. For those medicines that do, the returns for patient investors can be stellar, as Sirtex Medical proves.

Looking to cure your portfolio by adding some high yielding ASX shares? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!